Recherche

Two-thirds (66%) of Quebec homeowners plan to renovate within the next three years

Retrieved on: 
Monday, February 26, 2024
Climate, News, Sale, Mouth, Recherche, Motivation, Housing, Ageing, Real estate

Even though the economic situation isn’t ideal, homeowners want to keep maintaining their property.

Key Points: 
  • Even though the economic situation isn’t ideal, homeowners want to keep maintaining their property.
  • Many homeowners are therefore choosing to spend more time brainstorming and planning the projects they want to undertake, which is great news in and of itself!
  • In order to respond to their various housing needs, three out of four Quebec homeowners (76%) currently plan to undertake renovations instead of buying a new property (24%).
  • Among those planning to renovate, 33% expect it will be done in the next year, a significant drop from 2023 (42%).

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Retrieved on: 
Thursday, December 7, 2023
Immunotherapy, Recherche, ASX, Research, European, IMM, Cancer, Calendar, CIR, Immutep, Eftilagimod alpha

SYDNEY, AUSTRALIA, Dec. 07, 2023 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR).

Key Points: 
  • The “Crédit d’Impôt Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
  • Immutep qualifies for the CIR tax incentive through its subsidiary Immutep S.A.S.
  • Immutep also qualifies for cash rebates from the Australian Federal Government’s R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia.
  • As previously announced, in October 2023, the company received an A$1.13 million cash rebate from the Australian Federal Government’s R&D tax incentive program for the eligible R&D activities conducted in financial year 2022.

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

Retrieved on: 
Monday, November 27, 2023
SCD, Database, Polymerization, Recherche, Sickle cell disease, Partnership, Thalassemia, Risk, AP-HP, Death, Hemolytic anemia, Research, B cell, Basophil, VOC, FYN, Assistance, Mortality, Health, Disease, Acute chest syndrome, KIT, RBC, Mouse, Human, Life expectancy, Investment, Euronext, SCIENCE, Inflammation, Patent, Science, CELL, Public, Biomarker, Toxicity, RHU, Histamine, Child, Patient, APHP, Substance P, LYN, ACS, Pharmaceutical industry

THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".

Key Points: 
  • THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".
  • A new patent has been filed, which, if granted, will extend the international protection of masitinib in sickle cell disease until 2040.
  • Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease.
  • There is a significant medical need to prevent the acute and chronic complications of sickle cell disease.

VALBIOTIS SA:

Retrieved on: 
Thursday, December 14, 2023
Morale, BPI, Recherche, Force majeure, Furniture, Pension fund

Valbiotis est une entreprise de Recherche & Développement à dimension commerciale, engagée dans l’innovation scientifique, pour la prévention et la lutte contre les maladies métaboliques et cardiovasculaires en réponse aux besoins médicaux non satisfaits.

Key Points: 
  • Valbiotis est une entreprise de Recherche & Développement à dimension commerciale, engagée dans l’innovation scientifique, pour la prévention et la lutte contre les maladies métaboliques et cardiovasculaires en réponse aux besoins médicaux non satisfaits.
  • En France, la commercialisation sera assurée en propre par Valbiotis.
  • Valbiotis est une entreprise éligible au PEA-PME.
  • Pour plus d'informations sur Valbiotis, veuillez consulter : www.valbiotis.com

PENELOPE and the Beauty Bar's MEDISPA Division Celebrates First Anniversary, Introduces New MediSpa Treatments

Retrieved on: 
Monday, October 3, 2022
Smart contract, Muscle, MBR, Incontinence, FDA, EMS, Fairmont Olympic Hotel, Abdomen, Robert-Bourassa Boulevard — University Street, Beauty, Hair removal, Time-invariant system, PRP, IPL, Electrical muscle stimulation, Recherche, Forma, Beauty salon

Seattle's PENELOPE and the Beauty Bar Celebrates First Anniversary of MediSpa Division, Introduces New MediSpa Treatments

Key Points: 
  • Seattle's PENELOPE and the Beauty Bar Celebrates First Anniversary of MediSpa Division, Introduces New MediSpa Treatments
    Three new MediSpa treatments are being added to the current menu this fall.
  • RF toning, which utilizes Electrical Muscle Stimulation (EMS) which helps refine, restore, and improve the look and strength of muscles in the abdomen.
  • PENELOPE and the Beauty Bar is located in the historic Fairmont Olympic Hotel at 411 University Street, Seattle, WA 98101.
  • For more information on PENELOPE and the Beauty Bar and PENELOPE MEDISPA, please visit www.penelopeandthebeautybar.com .

Immutep Receives A$2.7 million R&D Tax Incentive from French Government

Retrieved on: 
Friday, September 23, 2022
ASX, Eftilagimod alpha, Autoimmune disease, French Government of the Hundred Days, CIR, Infection, Australian Securities Exchange, Antibody, Calendar, Immunotherapy, IMM, Patient, Cancer, Technology, Immutep, Recherche, Degenerative disease, 2009 Australian federal budget, LAG-3, NASDAQ, Research, GLOBE, R, Union, APC, Health insurance, Vaccine

The Crdit dImpt Recherche (CIR), meaning Research Tax Credit, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.

Key Points: 
  • The Crdit dImpt Recherche (CIR), meaning Research Tax Credit, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
  • Immutep qualifies to receive the CIR tax incentive through its subsidiary Immutep S.A.S.
  • Immutep also qualifies for cash rebates from the Australian Federal Governments R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

Retrieved on: 
Wednesday, September 29, 2021
Australian Securities Exchange, Recherche, French Government of the Hundred Days, Degenerative disease, NASDAQ, Cancer, Patient, APC, Infection, Immunotherapy, Immutep, Company, Antibody, ASX, Technology, IMM, 2009 Australian federal budget, Research, LAG-3, R, Autoimmune disease, CIR, GLOBE, Health insurance, Vaccine

The Crdit dImpt Recherche (CIR), meaning Research Tax Credit, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.

Key Points: 
  • The Crdit dImpt Recherche (CIR), meaning Research Tax Credit, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
  • Immutep qualifies to receive CIR tax incentive through its subsidiary Immutep S.A.S.
  • Immutep also qualifies for cash rebates from the Australian Federal Governments R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.